# Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study)

> **NCT01733394** · PHASE4 · COMPLETED · sponsor: **University of Cincinnati** · enrollment: 54 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Lamotrigine Generic "A" Lamotrigine Generic "B" Lamotrigine "Brand"
- **DRUG:** lamotrigine

## Key facts

- **NCT ID:** NCT01733394
- **Lead sponsor:** University of Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-12
- **Primary completion:** 2016-09-26
- **Final completion:** 2016-09-26
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2017-07-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01733394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01733394, "Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01733394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*